# Persistence of Antibody Response to N. Meningitidis Group C in Children

> **NCT00316654** · PHASE4 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 489 (actual)

## Conditions studied

- Prevention of Meningococcal Infection

## Interventions

- **BIOLOGICAL:** Meningococcal C conjugate vaccine

## Key facts

- **NCT ID:** NCT00316654
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 489 (ACTUAL)
- **Last updated:** 2017-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00316654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00316654, "Persistence of Antibody Response to N. Meningitidis Group C in Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00316654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*